Export 24 results:
Author Title [ Type(Desc)] Year
Filters: Author is Almeida, M.R.  [Clear All Filters]
Journal Article
Macedo, B., Batista, A. R., Ferreira, N., Almeida, M. R., & Saraiva, M. J. (2008). Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1782(9), 517 - 522.
Ferreira, N., Cardoso, I., Domingues, M. R., Vitorino, R., et al. (2009). Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 583(22), 3569 - 3576.
Sant'Anna, R., Almeida, M. R., Varejao, N., Gallego, P., et al. (2017). Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 7.
Almeida, M. R., & Saraiva, M. J. (2012). Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 586(18), 2891 - 2896.
Cardoso, I., Almeida, M. R., Ferreira, N., Arsequell, G., et al. (2007). Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochemical Journal, 408(1), 131 - 138.
Ferreira, N., Gonçalves, N. P., Saraiva, M. J., & Almeida, M. R. (2016). Curcumin: A multi-Target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 6.
Ferreira, N., Santos, S. A. O., Domingues, M. R. M., Saraiva, M. J., & Almeida, M. R. (2013). Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1832(1), 39 - 45.
Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2012). Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "In vivo" evidence from FAP mice models. PLoS ONE, 7(1).
Pessoa, J., Sárkány, Z., Ferreira-Da-Silva, F., Martins, S., et al. (2010). Functional characterization of Arabidopsis thaliana transthyretin-like protein. BMC Plant Biology, 10.
Martinho, A., Gonçalves, I., Cardoso, I., Almeida, M. R., et al. (2010). Human metallothioneins 2 and 3 differentially affect amyloid-beta binding by transthyretin. FEBS Journal, 277(16), 3427 - 3436.
Magalhães, V., Veiga-Malta, I., Almeida, M. R., Baptista, M., et al. (2007). Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes and Infection, 9(11), 1276 - 1284.
Gales, L., Almeida, M. R., Arsequell, G., Valencia, G., et al. (2008). Iodination of salicylic acid improves its binding to transthyretin. Biochimica et Biophysica Acta - Proteins and Proteomics, 1784(3), 512 - 517.
Mairal, T., Nieto, J., Pinto, M., Almeida, M. R., et al. (2009). Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE, 4(1).
Mairal, T., Nieto, J., Pinto, M., Almeida, M. R., et al. (2009). Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE, 4(1).
González, A., Quirante, J., Nieto, J., Almeida, M. R., et al. (2009). Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 19(17), 5270 - 5273.
Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2012). Natural polyphenols as modulators of TTR amyloidogenesis: In vitro and in vivo evidences towards therapy. Amyloid, 19(SUPPL. 1), 39 - 42.
Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2011). Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 585(15), 2424 - 2430.
Simões, C. J. V., Almeida, Z. L., Costa, D., Jesus, C. S. H., et al. (2016). A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 121, 823 - 840.
Sant'Anna, R., Gallego, P., Robinson, L. Z., Pereira-Henriques, A., et al. (2016). Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 7.
Almeida, M. R., Macedo, B., Cardoso, I., Alves, I., et al. (2004). Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 381(2), 351 - 356.
Almeida, M. R., Gales, L., Damas, A. M., Cardoso, I., & Saraiva, M. J. (2005). Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Current Drug Targets: CNS and Neurological Disorders, 4(5), 587 - 596.
Liz, M. A., Fleming, C. E., Nunes, A. F., Almeida, M. R., et al. (2009). Substrate specificity of transthyretin: Identification of natural substrates in the nervous system. Biochemical Journal, 419(2), 467 - 474.
Ferreira, N., Pereira-Henriques, A., & Almeida, M. R. (2015). Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors. Biochemistry and Biophysics Reports, 3, 123 - 133.
Saraiva, M. J., Magalhaes, J., Ferreira, N., & Almeida, M. R. (2012). Transthyretin deposition in familial amyloidotic polyneuropathy. Current Medicinal Chemistry, 19(15), 2304 - 2311.

Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@ibmc.up.pt | © copyright 2010 ibmc